bluebird bio Inc. (BLUE) and Celgene (CELG) have released results from the ongoing CRB-401 Phase 1 clinical study of bb2121. "We are encouraged by the duration and depth of responses, and pleased that the safety profile remains readily manageable," said David Davidson, M.D., chief medical officer, bluebird bio.
from RTT - Before the Bell http://ift.tt/2qXjhZr
via IFTTT
No comments:
Post a Comment